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Abstract
 
Background
 
: In Iran, there is insufficient information on the efficacy of 
 
Helicobacter pylori
 
 eradication
regimens shorter than 10 days. This study aims at assessing the efficacy of 4- and 7-day 
 
H. pylori
 
 erad-
ication regimens in a high-incidence area of gastric cancer in Iran.
 
Methods
 
: Subjects with an endoscopic diagnosis of gastritis, positive urease test, and a histological diag-
nosis of chronic gastritis were enrolled. Patients were randomly assigned to one of three groups: AOC7
(1000 mg amoxicillin, 20 mg omeprazole, and 500 mg clarithromycin twice daily for 7 days), FOT4
(200 mg furazolidone, 20 mg omeprazole, and 500 mg tetracycline twice daily for 4 days) and FOT7 (the
same treatment as the FOT4 group but for 7 days). Sensitivity to these antibiotics was determined in all
isolates recovered from culture. The efficacy of eradication was assessed 8 weeks after the end-of-
treatment by the 
 
14
 
C-urea breath test.
 
Results
 
: One hundred and twenty-eight patients were enrolled in the study. Culture was positive for
84 patients and none of these were resistant to amoxicillin, tetracycline or furazolidone, 1.2% were
resistant to clarithromycin and 32.1% to metronidazole. Forty-five, 41 and 42 patients were randomly
allocated to the AOC7, FOT4, and FOT7 groups, respectively. The intention-to-treat eradication rates
were 35.5, 17.1, and 23.8% for the AOC7, FOT4, and FOT7 groups, respectively.
 
Conclusion
 
: Treatment regimens of 4 or 7 days are unacceptable for 
 
H. pylori
 
 infection in Iran, even in
the presence of a favorable sensitivity profile.
© 2003 Blackwell Publishing Asia Pty Ltd
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INTRODUCTION
 
Helicobacter pylori
 
 eradication is now well established as
the first line of therapy for peptic ulcer disease.
 
1
 
 
 
Helico-
bacter pylori
 
 eradication was found to be ineffective in
treating non-ulcer dyspepsia, and the ideal therapy for
this entity is still debated. The role of 
 
H. pylori
 
 eradica-
tion in reduction of the long-term risk of gastric carci-
noma is also not clear.
 
2
 
 Although, a recent study from
Japan by Uemura 
 
et al.
 
, which is the first long-term
prospective comparison between 
 
H. pylori
 
-infected and
non-infected patients, has shown that non-ulcer dys-
pepsia patients with 
 
H. pylori
 
 infection have a near 5%
risk of developing gastric cancer during an 8-year follow
up.
 
3
 
 Therefore, 
 
H. pylori
 
 eradication may be indicated in
non-ulcer dyspepsia on the basis of the risk of gastric
cancer alone.
 
4
 
Gastric cancer is the second most common cause of
cancer-related mortality in the world,
 
5,6
 
 and is the most
common gastrointestinal malignancy in Iran (AR
Sajjadi, unpubl. data, 2000).
 
7
 
 Ardabil province, north-
west of Iran, was reported to have the highest incidence
 14
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of gastric cancer throughout the country, with an inci-
dence rate of 48.90 and 26.77 per 100 000 per year in
men and women, respectively. This constitutes 30% of
all types of malignancy in this province (AR Sajjadi,
unpubl. data, 2000). The prevalence of 
 
H. pylori
 
 infec-
tion is approximately 95% in Ardabil. If 
 
H. pylori
 
 eradi-
cation proves to be justified for prevention of gastric
carcinoma, which seems very likely, the selection of a
nonexpensive, safe, and effective antibiotic regimen is
very important. Decreasing the cost of eradication
can be accomplished by using cheaper medications,
and/or reducing the total duration of antibiotic therapy
while maintaining a high eradication rate.
In an attempt to decrease the cost of eradication,
many investigators have tried shorter courses of treat-
ment with various success rates. A shorter course is also
easier to comply with. Many studies, notably those from
Europe, have very good success rates with courses as
short as 3 days.
 
8–13
 
 In contrast, other studies do not.
 
14–16
 
In this study, we have compared the efficacy of three
4- and 7-day 
 
H. pylori
 
 eradication regimens in patients
with chronic gastritis from Ardabil.
 
METHODS
 
The study was performed in conjunction with a pilot
endoscopic cancer-screening survey in Ardabil. The
cancer-screening pilot included a random selection of
500 individuals, 40-years-old or older, living in the
Ardabil district. From these patients, we selected all
consenting subjects with an endoscopic diagnosis of
corpus predominant gastritis, positive rapid urease test,
and a histological diagnosis of 
 
H. pylori
 
-related chronic
gastritis who underwent endoscopic evaluation during a
3-day period. The study was approved by the ethics
committee of the Department of Internal Medicine of
Tehran University of Medical sciences.
The enrolled patients were then randomly allocated
to one of three groups. The AOC7 group was treated
with 1000 mg amoxicillin, 20 mg omeprazole, and
500 mg clarithromycin twice daily for 7 days. The FOT4
group was treated by 200 mg furazolidone, 20 mg ome-
prazole, and 500 mg tetracycline twice daily for 4 days.
The FOT7 group received the same treatment as
the FOT4 group but for 7 days. The AOC7 combination
was chosen because of reports of its high success in var-
ious studies, sometimes with other proton pump inhib-
itors (PPI) used instead of omeprazole.
 
10–12
 
 The FOT4
and FOT7 combinations were selected because of our
previous experience in Iran showing that furazolidone is
a cheap and effective substitute for clarithromycin.
 
17
 
Helicobacter pylori
 
 culture was performed for all isolates,
and sensitivity tests were performed for culture-positive
isolates.
Based on previous reports, we were expecting an 85%
eradication rate.
 
8–13
 
 To have a power of 80% to detect a
20% difference in eradication rates, 40 cases would be
required in each group.
Biopsies from the antrum were cultured on brucella
agar supplemented with 5–7% sheep blood, amphoteri-
cin B (6 mg/L), vancomycin (10 mg/L), trimethoprim
(5 mg/L), and polymixin B (2500 IU/L). Sensitivity to
metronidazole, furazolidone and clarithromycin was
determined by agar dilution,
 
18
 
 and sensitivity to amoxi-
cillin and tetracycline by the disc diffusion method.
 
19
 
Resistant strains were defined as those that grew on the
egg yolk agar medium containing more than 8 g/mL
metronidazole, 2
 
µ
 
g/mL clarithromycin, or 0.5
 
µ
 
g/mL
furazolidone, and those with a growth-inhibition zone
diameter of equal or less than 13 mm for amoxicillin
and 14 mm for tetracycline.
 
20
 
Patients were given both verbal and written instruc-
tions about the importance of taking the medications
regularly and not to stop medication on the event of
mild side-effects. They were also instructed to report
moderate or severe side-effects to one of the two local
members of the research team.
For the assessment of compliance and side-effects, all
cases were visited 10 days after the start of therapy.
Compliance was assessed by the percentage of medica-
tions used. It was considered excellent, good, or poor
when 90, 80, or 70% of the provided medicine was
taken by the patient, respectively. Side-effects were eval-
uated by direct questioning at the same visit. The effi-
cacy of eradication was assessed 8 weeks after the end of
treatment by the 
 
14
 
C-urea breath test as described by
Raju 
 
et al
 
.
 
21
RESULTS
 
One-hundred and twenty-eight patients were enrolled
in the study. Seventy-seven patients (60%) had occa-
sional dyspepsia defined as mild epigastric discomfort
at least once a week. The other subjects had no gas-
trointestinal symptoms. Forty-five, 41 and 42 patients
were randomly allocated to the AOC7, FOT4, and
FOT7 groups, respectively. The demographic charac-
teristics of the patients in all three groups were com-
parable and are given in Table 1. On endoscopic
examination, no patient had peptic ulcers, erosions or
findings other than described by the endoscopist as
gastritis. Forty-six (36%) of our patients were found to
have gastric atrophy on histological examination, and
12 (9%) had intestinal metaplasia.
Cultures were positive in 84 cases. None of the pos-
itive cultures were resistant to amoxicillin, furazolidone
or tetracycline, 1.2% were resistant to clarithromycin
and 32.1% to metronidazole. There were no significant
differences in antibiotic sensitivity between the three
groups. The compliance was excellent in all patients.
There were no significant differences in compliance
between the three groups. Side-effects were mild and no
patient discontinued medication because of side-effects.
A few side-effects (bad taste, nausea, oral ulcers), were
significantly more common in the FOT7 group.
Eighteen patients were lost on the follow-up visit
for evaluating the eradication rate. The per-protocol
eradication rates were 42.1, 20.6 and 29.4% for the
AOC7, FOT4, and FOT7 groups, respectively, and the
intention-to-treat rates were 35.5, 17.1, and 23.8%,
respectively. The difference between the eradication
rates was only marginally significant between the AOC7
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and FOT4 groups (
 
P
 
=
 
0.044 for per-protocol, and
 
P
 
=
 
0.045 for intention-to-treat).
 
DISCUSSION
 
Helicobacter pylori
 
 eradication using short-term regi-
mens is highly attractive because of the cheaper cost and
better patient compliance involved. Many studies have
evaluated shorter courses of regimens proven to be
effective when given for 10 or 14 days.
 
8,10–12,22–24
 
 The
AOC combination is one such regimen, and many
studies confirm its efficacy when given for 4 or 7 days.
Furazolidone-based regimens have also been shown to
be very effective and less expensive substitutes for
clarithromycin-based regimens.
 
22,23,25–27
 
 There are also
a few studies reporting relatively good results with 7-day
courses of furazolidone-based regimens.
 
22,23
 
In Iran, many studies have addressed the issue of
the optimal treatment for 
 
H. pylori
 
 eradication. Most
studies from Iran have evaluated treatment regimens
of 10 days or more, and the eradication rate in ulcer
patients has been shown to be lower than similar reports
from Europe, America and China.
 
14,17,25,28–30
 
 Studies
on short-term treatments in Iran have reported very
poor results. In a recent report, a 7-day regimen in
patients with duodenal ulcers resulted in an unaccept-
able eradication rate of 23.8%. This study used bis-
muth, amoxicillin, metronidazole, and ranitidine. The
same regimen resulted in an eradication rate of 62.5%
when given for 2 weeks.
 
14
 
In the present report, we demonstrate that 4- and 7-
day courses of a furazolidone-based, and a 7-day course
of a clarithromycin-based regimen are clearly inef-
ficient, even though we have a favorable 
 
H. pylori
 
sensitivity.
Our sample size was computed to provide a power of
80%, assuming an 85% eradication rate. However, with
the unexpectedly low eradication rates obtained (mean
31%), the power of our study for detecting differences
between each treatment group would be too low
(approximately 65% for a 20% difference). The major
point of our study is the unacceptably low rates
obtained with any of the three regimens.
It should be noted that our patients were without sig-
nificant symptoms and did not have duodenal or gastric
ulcers. It is well known that eradicating 
 
H. pylori
 
 in this
setting is more difficult.
 
23,31
 
 Studies evaluating eradica-
tion rates of 
 
H. pylori
 
 in non-ulcer dyspepsia usually
report rates 10–15% less than those in patients with
ulcers.
 
23,31
 
 But the eradication rates we have obtained in
this study are much less. All our subjects had excellent
compliance, so the reason for this low eradication rate
should lie elsewhere.
Differences between infecting strains of 
 
H. pylori
 
 have
already been shown to be important in the efficacy
of eradication.
 
32
 
 Low eradication rates in non-ulcer
patients may be linked to the CagA status of isolates.
CagA-positive strains are more prevalent in ulcer
patients than in non-ulcer patients.
 
33
 
 Furthermore,
less virulent strains (CagA negative, Vac S2) are more
difficult to eradicate than the more virulent strains
(CagA positive, Vac S1).
 
34
 
Ardabil is a high-prevalence area for gastric cancer.
Considering the known association of gastric cancer
with 
 
H. pylori
 
 infection, it is likely that the 
 
H. pylori
 
strains associated with gastric cancer are biologically
different from those that are not. It is probable that the
cancer-associated 
 
H. pylori
 
 is more difficult to treat.
Further research into the phenotype of the 
 
H. pylori
 
strain and the profile of host-immune response is
necessary in order to explain the very low eradication
rate we encountered in Ardabil.
Another probable reason for the low eradication rates
may lie in the fact that, in an endemic area such as Ard-
abil, there may be a higher load of bacteria in the gastric
mucosa.
 
35
 
 We have already shown that 
 
H. pylori
 
 infec-
tion in Ardabil is acquired at a younger age. In a study
of patients younger than 14 years old, 47.5% of subjects
from Ardabil were infected as compared with 30.6%
from Yazd, a city in central Iran with a low incidence of
gastric cancer.
 
36
 
 Higher densities of 
 
H. pylori
 
 in gastric
mucosa may have resulted from acquiring infection at
an earlier age with a less virulent strain, resulting in
poor host-immune response. Such an infection is diffi-
cult to eradicate with 4- or 7-day regimens and further
trials with bismuth-based quadruple therapies of at least
10-day duration are warranted. Eradication may also
need to be started earlier in life in order to be more
effective.
In conclusion, the 4- and 7-day PPI-based triple ther-
apies used in this study, in spite of the good sensitivity
profile, do not seem to be effective in this population
and should not be used.
 
Table 1
 
Baseline demographic and clinical characteristics of patients who participated in the 
 
Helicobacter pylori
 
 eradication trial
in Ardabil province, Iran
AOC7 FOT7 FOT4
No. patients 45 42 41
Male/female 17/28 21/21 25/16
Mean age
 
±
 
SD (years) 55.07
 
±
 
10.84 52.41
 
±
 
9.18 51.78
 
±
 
9.14
Age range (years) 40–73 40–73 40–69
Smoker (
 
>
 
10 cigarettes/day) 7 4 5
Non-steroidal anti-inflammatory drug use 9 6 6
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